CAS 23599-69-1: (+)-Norisoboldine

Norisoboldine is a drug that inhibits the activity of P-glycoprotein (P-gp) and has significant cytotoxicity. Norisoboldine has been shown to have therapeutic potential for the treatment of bowel disease, including ulcerative colitis and Crohn's Disease. This drug also inhibits the production of proinflammatory cytokines such as IL-10, which may play a role in its therapeutic effects. Norisoboldine has been shown to inhibit mitochondrial membrane potential and to be an anti-inflammatory agent. It also has a high bioavailability in vivo, which may be due to its ability to bind tightly to human serum proteins.

Natural alkaloid

(S)-2,10-Dimethoxy-5,6,6A,7-Tetrahydro-4H-Dibenzo[De,G]Quinoline-1,9-Diol

Norisoboldine, potential rheumatoid arthritis therapy, protects joints and modulates immunity by inhibiting MAPKs, not NF-κB.

Norisoboldine is the main isoquinoline alkaloid occurring in Radix Linderae, the dry roots of Lindera aggregata (Lauraceae family),it has been previously implicated to be able to ameliorate the synovial inflammation and abnormal immune conditions in collagen-induced arthritis of mice; it inhibits the macrophage activation and the resultant production of pro-inflammatory cytokines via down-regulating the activation of MAPKs signaling pathways rather than NF-κB.